- Home
- USIO vs COEP Comparison
USIO vs COEP Comparison
Compare USIO & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USIO
- COEP
- Stock Information
- Founded
- USIO 1998
- COEP 2017
- Country
- USIO United States
- COEP United States
- Employees
- USIO N/A
- COEP N/A
- Industry
- USIO Investment Bankers/Brokers/Service
- COEP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- USIO Finance
- COEP Health Care
- Exchange
- USIO Nasdaq
- COEP Nasdaq
- Market Cap
- USIO 37.1M
- COEP 32.0M
- IPO Year
- USIO N/A
- COEP N/A
- Fundamental
- Price
- USIO $1.65
- COEP $7.63
- Analyst Decision
- USIO Strong Buy
- COEP
- Analyst Count
- USIO 1
- COEP 0
- Target Price
- USIO $4.00
- COEP N/A
- AVG Volume (30 Days)
- USIO 86.9K
- COEP 31.8K
- Earning Date
- USIO 08-13-2025
- COEP 08-15-2025
- Dividend Yield
- USIO N/A
- COEP N/A
- EPS Growth
- USIO N/A
- COEP N/A
- EPS
- USIO 0.12
- COEP N/A
- Revenue
- USIO $83,970,504.00
- COEP $62,874.00
- Revenue This Year
- USIO $16.33
- COEP N/A
- Revenue Next Year
- USIO $14.56
- COEP N/A
- P/E Ratio
- USIO $13.54
- COEP N/A
- Revenue Growth
- USIO 0.46
- COEP N/A
- 52 Week Low
- USIO $1.24
- COEP $2.31
- 52 Week High
- USIO $2.92
- COEP $13.70
- Technical
- Relative Strength Index (RSI)
- USIO 70.84
- COEP 40.22
- Support Level
- USIO $1.32
- COEP $7.25
- Resistance Level
- USIO $1.69
- COEP $8.86
- Average True Range (ATR)
- USIO 0.08
- COEP 0.60
- MACD
- USIO 0.03
- COEP -0.02
- Stochastic Oscillator
- USIO 81.08
- COEP 35.89
About USIO Usio Inc.
Usio Inc is a United States-based company that provides integrated electronic payment services, including credit and debit card-based processing services and transaction processing via the Automated Clearing House, or ACH network to billers and retailers. The Company also has an additional wholly-owned subsidiary, which is the entity for Output Solutions operations.
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.